141 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27890381	2	Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei.	Johannes Gutenberg University
27994740	41	Dipeptidyl Nitroalkenes as Potent Reversible Inhibitors of Cysteine Proteases Rhodesain and Cruzain.	Universitat Jaume I
27214508	43	Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S.	Cnrs
27690432	75	Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).	Charles River Discovery Research Services
26881908	13	De Novo Design at the Edge of Chaos.	Swiss Federal Institute of Technology (Eth)
26985300	110	Cathepsin B Inhibitors: Combining Dipeptide Nitriles with an Occluding Loop Recognition Element by Click Chemistry.	University of Bonn
26462052	29	Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.	Baylor University
26280490	17	Development of N-(Functionalized benzoyl)-homocycloleucyl-glycinonitriles as Potent Cathepsin K Inhibitors.	National Institute of Chemistry
25571794	40	Structure-based design and optimization of potent inhibitors of the adenoviral protease.	Novartis Institute For Biomedical Research
25375026	14	Structures and bioactivities of dihydrochalcones from Metrodorea stipularis.	Universidade Federal De S£O Carlos
25313327	11	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.	Eli Lilly
25313316	20	3-Cyano-3-aza-ß-amino Acid Derivatives as Inhibitors of Human Cysteine Cathepsins.	University of Bonn
24592859	59	Cathepsin C inhibitors: property optimization and identification of a clinical candidate.	Astrazeneca
23145854	9	Principles and applications of halogen bonding in medicinal chemistry and chemical biology.	Eberhard-Karls University
23252745	86	Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.	University of Ljubljana
24900293	78	Discovery of novel cyanamide-based inhibitors of cathepsin C.	TBA
19616430	120	Design of selective Cathepsin inhibitors.	Astrazeneca
16546382	100	Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.	Celera Genomics
23084902	116	Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement.	Boehringer Ingelheim Pharmaceuticals
23167554	28	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.	Universidade Federal De Pernambuco
22984809	111	Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors.	Astrazeneca
22742641	113	(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis.	Astrazeneca
22686657	60	Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F.	University of Bonn
22858142	121	Isosteric replacements for benzothiazoles and optimisation to potent Cathepsin K inhibitors free from hERG channel inhibition.	Astrazeneca
24900494	72	Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.	TBA
22591648	78	Evaluation of synthetic acridones and 4-quinolinones as potent inhibitors of cathepsins L and V.	Universidade Federal De S£O Carlos
22236250	16	Exploring activity cliffs in medicinal chemistry.	Rheinische Friedrich-Wilhelms-Universit£T
21128614	76	Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors.	University of Bonn
20598553	38	Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors.	Universit£
19709887	25	Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors.	Universit£
19419206	77	Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity.	Ewha Womans University
17535802	91	Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.	Merck Research Laboratories
18420405	26	Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB.	University of California
18499453	8	Design, synthesis, and evaluation of inhibitors of cathepsin L: Exploiting a unique thiocarbazate chemotype.	University of Pennsylvania
18375120	45	New chemotypes for cathepsin K inhibitors.	Novartis Institutes For Biomedical Research
18060772	5	Identification and synthesis of a unique thiocarbazate cathepsin L inhibitor.	University of Pennsylvania
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18232656	30	Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors.	University of Messina
18226527	80	The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.	Merck Frosst Centre For Therapeutic Research
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
9784105	68	Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.	Takeda Chemical Industries
21420760	8	Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors.	University of Messina
21733692	56	Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.	Glaxosmithkline
21227690	68	1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors: separation of desired cellular activity from undesired tissue accumulation through optimization of basic nitrogen pka.	Merck Research Laboratories
21041084	102	Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.	Merck Research Laboratories
21030256	61	Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors.	Merck Research Laboratories
20933415	50	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.	Baylor University
20843687	60	Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG.	Merck Research Laboratories
19841155	29	MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.	Merck Research Laboratories
20692829	21	Allicin and derivates are cysteine protease inhibitors with antiparasitic activity.	University of WüRzburg
20594841	123	2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.	Merck Research Laboratories
20153187	32	Dioxo-triazines as a novel series of cathepsin K inhibitors.	Schering-Plough
20149657	53	Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.	Schering-Plough
19665376	48	Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.	Merck Frosst Canada
20089402	72	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.	Baylor University
19769357	93	Structure-guided development of selective TbcatB inhibitors.	University of California
	22	Inhibition of human erythrocyte calpain I by novel quinolinecarboxamides	TBA
19296600	14	Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors.	University of Messina
19231183	44	5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.	Astrazeneca
19124252	141	Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.	Medivir
18783943	35	Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.	Novartis Institutes For Biomedical Research
18707091	14	Effect of cathepsin K inhibitors on bone resorption.	Novartis Institutes For Biomedical Research
18701300	55	Synthesis and elastase-inhibiting activity of 2-pyridinyl-isothiazol-3(2H)-one 1,1-dioxides.	University of Leipzig
18662880	56	4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors.	Novartis Institutes For Biomedical Research
18572405	85	Discovery of selective and nonpeptidic cathepsin S inhibitors.	Novartis Institutes For Biomedical Research
18571402	24	Effect of novel N-cyano-tetrahydro-pyridazine compounds, a class of cathepsin K inhibitors, on the bone resorptive activity of mature osteoclasts.	Korea Research Institute of Chemical Technology
17544269	30	Primary amides as selective inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
17196818	90	Bicyclic carbamates as inhibitors of papain-like cathepsin proteases.	The Genomics Institute of The Novartis Research Foundation
16750630	28	Design and synthesis of tetracyclic nonpeptidic biaryl nitrile inhibitors of cathepsin K.	Celera Genomics
16647256	16	Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.	Arpida
16302794	53	Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.	Celera Genomics
16290936	69	Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?	Glaxosmithkline
16250645	35	Azepanone-based inhibitors of human cathepsin L.	Glaxosmithkline
16216498	2	Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.	University of WüRzburg
16154747	37	Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.	Merck Frosst Centre For Therapeutic Research
15982880	86	P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15896958	32	Acyclic cyanamide-based inhibitors of cathepsin K.	Glaxosmithkline
15837295	55	A structural screening approach to ketoamide-based inhibitors of cathepsin K.	Glaxosmithkline
15780613	28	Novel and potent cyclic cyanamide-based cathepsin K inhibitors.	Glaxosmithkline
15537340	27	Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.	Novartis Institutes For Biomedical Research
15380210	18	Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).	University of Southern California
15341970	59	P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors.	Eli Lilly
15341947	57	Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions.	Glaxosmithkline
15261289	38	Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.	Merck Frosst Centre For Therapeutic Research
15177446	41	Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors.	Glaxosmithkline
14684338	44	P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors.	Eli Lilly
14684304	41	(4-Piperidinylphenyl)aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors.	Amgen
14592520	41	N-arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B.	Novartis Institute of Biomedical Research
12781193	36	3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity.	Ligand Pharmaceuticals
12781182	81	Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents.	Novartis Pharma
12467634	67	3-Acylamino-azetidin-2-one as a novel class of cysteine proteases inhibitors.	Currently Naeja Pharmaceutical
12431059	27	Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides.	National Research Council of Canada
12270191	36	General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.	University of California
12270170	42	Novel route to the synthesis of peptides containing 2-amino-1'-hydroxymethyl ketones and their application as cathepsin K inhibitors.	Celera
12036343	24	Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.	TBA
11992771	19	Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors.	Abbott
11814800	14	Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin.	Organon K.K.
11806719	61	Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis.	University of California
11741472	45	Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.	Novartis Pharmaceuticals
11356112	175	Potent reversible inhibitors of the protein tyrosine phosphatase CD45.	Astrazeneca Pharmaceuticals
11311061	40	Azepanone-based inhibitors of human and rat cathepsin K.	Glaxosmithkline
11141092	85	Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.	Merck Frosst Centre For Therapeutic Research
10937745	7	Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B.	Queen'S University Belfast
9733481	31	Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.	Smithkline Beecham Pharmaceuticals
7650671	15	Vinyl sulfones as mechanism-based cysteine protease inhibitors.	Khepri Pharmaceuticals
22397393	5	Synthesis of a-oxycarbanilinophosphonates and their anticholinesterase activities: the most potent derivative is bound to the peripheral site of acetylcholinesterase.	Institute For Advanced Studies In Basic Sciences (Iasbs)
21635213	8	In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II.	Balikesir University
1397049	24	NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists.	Novo Nordisk
15734651	135	A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.	National Institutes of Health